.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,030,312

« Back to Dashboard

Details for Patent: 8,030,312

Title:5-HT1A receptor subtype agonist
Abstract: The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT.sub.1A receptor subtype, comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1): ##STR00001## wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.
Inventor(s): Jordan; Shaun (Germantown, MD), Kikuchi; Tetsuro (Tokushima, JP), Tottori; Katsura (Kamiita-cho, JP), Hirose; Tsuyoshi (Tokushima, JP), Uwahodo; Yasufumi (Tokushima, JP)
Assignee: Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP)
Filing Date:Jun 28, 2004
Application Number:10/876,605
Claims:1. A method of treating a patient suffering from, obsessive compulsive disorder (OCD), which comprises administering to said patient a therapeutically effective amount of a carbostyril compound of formula (1), or a pharmaceutically acceptable salt, or a solvate thereof selected from hemihydrates, hydrates, and alcoholates, wherein said patient is a mammal: ##STR00003## wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.

2. The method according to claim 1, wherein the carbostyril compound is 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxyl}-3,4-dihydrocarbostyri- l.

3. A method of treating a patient suffering from alcohol addiction, which comprises administering to said patient a therapeutically effective amount of a carbostyril compound of formula (1), or a pharmaceutically acceptable salt, or a solvate thereof selected from hemihyd rates, hydrates, and alcoholates, wherein said patient is a mammal: ##STR00004## wherein the carbon-carbon bond between 3- and 4- positions in the carbostyril skeleton is a single or a double bond.

4. The method according to claim 3, wherein the carbostyril compound is 7-{4-[4-(2,3-diichlorophenyl)-1-piperazinyl]butoxy}-3,4-dihydrocarbostyri- l.

5. A method of treating a patient suffering from drug addiction, which comprises administering to said patient a therapeutically effective amount of a carbostyril compound of formula (1), or a pharmaceutically acceptable salt, or a solvate thereof selected from hemihyd rates, hydrates, and alcoholates, wherein said patient is a mammal: ##STR00005## wherein the carbon-carbon bond between 3- and 4- positions in the carbostyril skeleton is a single or a double bond.

6. The method according to claim 5, wherein the carbostyril compound is 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxyl}-3,4-dihydrocarbostyri- l.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc